For breast cancer prevention, use of endocrine modulators that target estrogen signaling or production, such as tamoxifen or letrozole, has proven to be a successful strategy to prevent and treat estrogen receptor-positive (ER+) breast cancers [1–3]. This evidence concerns the gene ESR1 and breast carcinoma.